Sign up to our newsletter Subscribe
An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

Sign up to our newsletter Subscribe
Biosimilars have similar, but not identical, structures to branded biologic drugs. Being comparable, but not interchangeable, they can differ in cost-effectiveness and accessibility. Increased competition, however, can reduce healthcare system costs.
An error has occurred, please try again later.